tetano
Editor, Senior Moderator
QJM
. 2021 Nov 26;hcab297.
doi: 10.1093/qjmed/hcab297. Online ahead of print.
Risk factors and incidence of Long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?
Lucio Boglione[SUP] 1 [/SUP], Giulia Meli[SUP] 1 [/SUP], Federica Poletti[SUP] 2 [/SUP], Roberto Rostagno[SUP] 2 [/SUP], Roberta Moglia[SUP] 2 [/SUP], Marco Cantone[SUP] 2 [/SUP], Maria Esposito[SUP] 2 [/SUP], Cristina Scianguetta[SUP] 2 [/SUP], Beatrice Domenicale[SUP] 2 [/SUP], Fortunata Di Pasquale[SUP] 2 [/SUP], Silvio Borrè[SUP] 2 [/SUP]
Affiliations
Abstract
Background: The definition of "Long-COVID syndrome" (LCS) is still debated and describes the persistence of symptoms after viral clearance in hospitalized or non-hospitalized patients affected by coronavirus disease 2019 (COVID-19).
Aim: In this study we examined the prevalence and the risk factors of LCS in a cohort of patients with previous COVID-19 and followed for at least six months of follow-up.
Design: We conducted a prospective study including all hospitalized patients affected by COVID-19 at our center of Infectious Diseases (Vercelli, Italy) admitted between 10th March 2020 to 15th January 2021 for at least six months after discharge. Two follow-up visits were performed: after 1 and six months after hospital discharge. Clinical, laboratory and radiological data were recorded at each visit.
Results: 449 patients were included in the analysis. The LCS was diagnosed in 322 subjects at visit 1 (71.7%) and in 206 at visit 2 (45.9); according to the PCFS scale we observed 147 patients with values 2-3 and 175 with values >3 at visit 1; at visit 2 133 subjects had the score between 2-3 and 73 > 3. In multivariate analysis, ICU admission (OR = 2.551; 95%CI = 1.998-6.819; p = 0.019), time of hospitalization (OR = 2.255; 95%CI = 1.018-6.992; p = 0.016) and treatment with remdesivir (OR = 0.641; 95%CI = 0.413-0.782; p < 0.001) were independent predictors of LCS.
Conclusions: Treatment with remdesivir leads to a 35.9% reduction in LCS rate in follow-up. Severity of illness, need of ICU admission and length of hospital stay were factor associated with the persistence of PCS at six months of follow-up.
Keywords: COVID-19; SARS-CoV-2; antiviral therapy; hospitalization; remdesivir.
. 2021 Nov 26;hcab297.
doi: 10.1093/qjmed/hcab297. Online ahead of print.
Risk factors and incidence of Long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?
Lucio Boglione[SUP] 1 [/SUP], Giulia Meli[SUP] 1 [/SUP], Federica Poletti[SUP] 2 [/SUP], Roberto Rostagno[SUP] 2 [/SUP], Roberta Moglia[SUP] 2 [/SUP], Marco Cantone[SUP] 2 [/SUP], Maria Esposito[SUP] 2 [/SUP], Cristina Scianguetta[SUP] 2 [/SUP], Beatrice Domenicale[SUP] 2 [/SUP], Fortunata Di Pasquale[SUP] 2 [/SUP], Silvio Borrè[SUP] 2 [/SUP]
Affiliations
- PMID: 34850210
- DOI: 10.1093/qjmed/hcab297
Abstract
Background: The definition of "Long-COVID syndrome" (LCS) is still debated and describes the persistence of symptoms after viral clearance in hospitalized or non-hospitalized patients affected by coronavirus disease 2019 (COVID-19).
Aim: In this study we examined the prevalence and the risk factors of LCS in a cohort of patients with previous COVID-19 and followed for at least six months of follow-up.
Design: We conducted a prospective study including all hospitalized patients affected by COVID-19 at our center of Infectious Diseases (Vercelli, Italy) admitted between 10th March 2020 to 15th January 2021 for at least six months after discharge. Two follow-up visits were performed: after 1 and six months after hospital discharge. Clinical, laboratory and radiological data were recorded at each visit.
Results: 449 patients were included in the analysis. The LCS was diagnosed in 322 subjects at visit 1 (71.7%) and in 206 at visit 2 (45.9); according to the PCFS scale we observed 147 patients with values 2-3 and 175 with values >3 at visit 1; at visit 2 133 subjects had the score between 2-3 and 73 > 3. In multivariate analysis, ICU admission (OR = 2.551; 95%CI = 1.998-6.819; p = 0.019), time of hospitalization (OR = 2.255; 95%CI = 1.018-6.992; p = 0.016) and treatment with remdesivir (OR = 0.641; 95%CI = 0.413-0.782; p < 0.001) were independent predictors of LCS.
Conclusions: Treatment with remdesivir leads to a 35.9% reduction in LCS rate in follow-up. Severity of illness, need of ICU admission and length of hospital stay were factor associated with the persistence of PCS at six months of follow-up.
Keywords: COVID-19; SARS-CoV-2; antiviral therapy; hospitalization; remdesivir.